BNP Paribas Arbitrage SA cut its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 70.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,846 shares of the biopharmaceutical company’s stock after selling 6,717 shares during the period. BNP Paribas Arbitrage SA’s holdings in Ocular Therapeutix were worth $40,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently modified their holdings of OCUL. Lindbrook Capital LLC increased its position in Ocular Therapeutix by 13.9% during the second quarter. Lindbrook Capital LLC now owns 8,200 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 1,000 shares during the last quarter. Centerpoint Advisors LLC boosted its position in shares of Ocular Therapeutix by 91.2% during the 2nd quarter. Centerpoint Advisors LLC now owns 2,390 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,140 shares in the last quarter. State of Wisconsin Investment Board lifted its position in Ocular Therapeutix by 1.4% in the 1st quarter. State of Wisconsin Investment Board now owns 101,800 shares of the biopharmaceutical company’s stock valued at $1,671,000 after acquiring an additional 1,400 shares in the last quarter. Swiss National Bank increased its stake in Ocular Therapeutix by 1.1% in the 1st quarter. Swiss National Bank now owns 138,600 shares of the biopharmaceutical company’s stock valued at $2,274,000 after buying an additional 1,500 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Ocular Therapeutix by 1.9% during the 2nd quarter. Rhumbline Advisers now owns 85,117 shares of the biopharmaceutical company’s stock worth $1,207,000 after purchasing an additional 1,591 shares during the last quarter. Institutional investors own 63.02% of the company’s stock.
Shares of OCUL opened at $11.54 on Thursday. The company’s 50-day simple moving average is $10.57 and its 200-day simple moving average is $13.11. The company has a debt-to-equity ratio of 0.63, a quick ratio of 10.00 and a current ratio of 10.05. Ocular Therapeutix, Inc. has a 1 year low of $9.11 and a 1 year high of $24.30. The stock has a market capitalization of $883.77 million, a PE ratio of -6.04 and a beta of 2.14.
OCUL has been the subject of several analyst reports. JMP Securities reissued a “buy” rating and issued a $33.00 price target on shares of Ocular Therapeutix in a report on Friday, October 8th. Piper Sandler reiterated a “buy” rating and issued a $28.00 target price on shares of Ocular Therapeutix in a research note on Friday, July 23rd. HC Wainwright upped their target price on shares of Ocular Therapeutix from $17.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research cut shares of Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Buy” and a consensus price target of $23.83.
In other news, CEO Antony C. Mattessich purchased 5,000 shares of the business’s stock in a transaction dated Friday, August 20th. The stock was acquired at an average price of $9.89 per share, with a total value of $49,450.00. Following the purchase, the chief executive officer now directly owns 102,900 shares of the company’s stock, valued at approximately $1,017,681. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.
Ocular Therapeutix Profile
Ocular Therapeutix, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL).
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.